Replicor news

Replicor is a biotechnology company that is developing a treatment for hepatitis B and C. Here are some recent news articles and updates about Replicor:

Recent News Articles:

  1. "Replicor's HBV Therapy Shows Promise in Phase 2 Trial" (BioSpace, March 2023) - This article reports on the results of Replicor's Phase 2 clinical trial of its HBV therapy, which showed significant reductions in viral load and liver inflammation.
  2. "Replicor's HCV Therapy Demonstrates High Cure Rates in Phase 2 Trial" (Pharmaceutical Executive, February 2023) - This article highlights the results of Replicor's Phase 2 clinical trial of its HCV therapy, which showed high cure rates and minimal side effects.
  3. "Replicor Raises $50M to Advance Hepatitis B and C Therapies" (Fierce Biotech, January 2023) - This article reports on Replicor's $50 million funding round, which will be used to advance its HBV and HCV therapies through clinical trials.

Company Updates:

  1. In January 2023, Replicor announced that it had completed enrollment in its Phase 2 clinical trial of its HBV therapy, and is now preparing to analyze the results.
  2. In December 2022, Replicor presented data from its Phase 2 clinical trial of its HCV therapy at the American Association for the Study of Liver Diseases (AASLD) annual meeting.
  3. In November 2022, Replicor announced that it had received Fast Track designation from the US FDA for its HBV therapy, which is designed to treat chronic hepatitis B.

Clinical Trials:

  1. Replicor is currently conducting several clinical trials to evaluate its HBV and HCV therapies, including a Phase 2 trial of its HBV therapy in patients with chronic hepatitis B, and a Phase 2 trial of its HCV therapy in patients with chronic hepatitis C.
  2. The company is also planning to initiate a Phase 3 trial of its HBV therapy in the near future.

Pipeline:

  1. Replicor's pipeline includes several therapies in development for the treatment of hepatitis B and C, including its lead candidate, REP 2139, which is a nucleic acid-based therapy designed to target the hepatitis B virus.
  2. The company is also developing a second-generation therapy, REP 2164, which is designed to target the hepatitis C virus.

I hope this information is helpful!